Connect with us

Micro Cap Insider

Major Move on PLYZ (Plyzer Technologies) Plyzer Intelligence; (AI) Machine Learning & Product Matching

Published

on

PLYZ (Plyzer Technologies Inc) is gearing up and heating up in recent months skyrocketing out of the triple zeroes and emerging well into pennyland with recent highs of $0.006 per share.  The stock has been under heavy accumulation recently and volume has picked up substantially with PLYZ regularly trading several 100 million shares per day and topped $1.5 million in dollar volume on Friday alone. Microcapdaily first covered PLYZ on December 8 when the stock was triple zeroes; since than PLYZ has risen dramatically as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than PLYZ has.   

There is a lot to get excited about on PLYZ; PLYZ built Plyzer Intelligence; a tool built on artificial intelligence through internally developed algorithms, machine learning, geo-localization and product matching. It allows companies to apply business intelligence to their decisions through the simplification of big data. Brands and retailers can learn more about how their products, as well as their competitors’ products, are performing online. PLYZ was trading over $0.20 per share this time last year with no material changes to the Company. According to their filings the Company’s Spain subsidiary, Plyzer Spain s.l., now has 35 full time employees including 9 freelancers. Investors are anxiously awaiting PLYZ earnings announcement for the period ending March 30, 2020 set to be released on Tuesday, February 16. 

PLYZ (Plyzer Technologies Inc) provides custom, real-time, cloud-based business intelligence solutions for brands to analyze critical online price and market data. Plyzer’s highly customizable dashboard enables country, regional and local sales, production and logistics operations to adapt to prevailing market conditions quickly. The Company’s technology is also being used to provide real-time price comparison reporting to the consumer market. These solutions are both driven by Plyzer’s proprietary artificial intelligence and machine learning technologies. Plyzer Technologies has offices in Barcelona, Spain and Toronto, Canada 

Image result for Plyzer Technologies IncThe Company has four subsidiaries, Plyzer Corporation, Plyzer Technologies (Canada) Inc. Plyzer BlockChain Technologies Inc., and Plyzer Technologies Spain s.l. According to PLYZ last 10k the Company’s Spain subsidiary Plyzer Spain s.l., now has 35 full time employees including 9 freelancers working full time for Plyzer Spain. Further hiring plans will depend on the continued implementation of the current business strategy and if the required funds are raised. It is likely that for now, the Company will resort to hiring consultants as and when needed rather than employ people on a full-time basis to keep its operational costs at a minimum. All the development was outsourced to Lupama and other independent consultants until incorporation of Plyzer Spain s.l. However, currently, the Company has most of the development and commercialization work carried out in-house. 

The Company has a consulting agreement with an independent Spanish Corporation, Lupama Producciones, S.L. Lupama’s key owner, Luis Pallares became the CEO of Plyzer Technologies (Canada) Inc. and Plyzer Corporation. Lupama is creating an artificial intelligence driven engine for price comparison for the Company, known as “Plyzer.” Lupama created Plyzer.com; a comparison engine for prices of over-the-counter medical products currently available in Spain and Canada. Users can search for the stores selling the products of their choosing focusing on the lowest prices but also by proximity. The prices of the products vary and are compared across more than 400 stores. 

PLYZ built Plyzer Intelligence; a tool built on artificial intelligence through internally developed algorithms, machine learning, geo-localization and product matching. It allows companies to apply business intelligence to their decisions through the simplification of big data. Brands and retailers can learn more about how their products, as well as their competitors’ products, are performing online. 

Microcapdaily first reported on PLYZ on December 8 when the stock was in the triple zeroes stating at the time: “Plyzer Technologies Inc (OTCMKTS: PLYZ) is making a powerful move up the charts in recent weeks trading billions of shares in the double zeroes and attracting legions of new shareholders who continue to accumulate and drive up the price. PLYZ was trading over $0.20 per share this time last year with no material changes to the Company. According to their filings the Company’s Spain subsidiary, Plyzer Spain s.l., now has 35 full time employees including 9 freelancers. Plyzer Spain subsidiary has made several announcements this year including signing Vitae Health Innovation, Global Life Sciences Company and Pharmaceutical Chiesi Spain as a new SAAS Customers for its business analytics platform, Plyzer intelligence. On November 13 PLYZ filed an 8k stating: “Management hopes to bring its filings current by early 2021.” 

On December 16 PLYZ provided an update on deal with YYZBCN financing group and settlement with the original founder and other corporate matters. Management states: “With respect to the filing of our year-end March 31/2020, the company has been able to gather most of the information needed to complete the filing. With respect to the quarters ending June 30/2020 and September 30/2020, the company has been gathering the necessary information to carry out the filing. Due to restrictions and difficulties surrounding Covid 19, the company has not been in a position to complete the filings on time. In addition, the CEO of the company had Covid 19 and was unable to work for almost a month. When the Q’s and Ks are completed, they will be filed with the SEC and attached to the company’s website. 

A settlement agreement was reached between the former CEO of Plyzer Spain, Luis Pallares, who was the original founder of the company and Plyzer Technologies/Plyzer Spain. The settlement averted litigation between the parties and ensured continuity of business within the operating company, Plyzer Spain. A cash payment of fifty thousand euros (50 k/Euros) plus twenty-four million (24 M) restricted shares of Plyzer Technologies will be made to Mr. Pallares. Mr. Pallares had previously returned twenty-four million shares to the treasury, so, the new shares being issued only represent what he originally had as a founding shareholder. Mr. Pallares no longer has any involvement in the company but has agreed to work with Plyzer Spain to resolve any issues that YYZBCN Inc. may encounter. The company wishes Mr. Pallares the best of success in his new ventures. 

Investor sentiment on PLYZ is high:

To Find out the inside Scoop on PLYZ Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

PLYZ

Further to the previous announcement concerning YYZBCN Inc.’s (YYZ) financing of Plyzer Spain, YYZ has now advanced approximately EUR 960 K in senior equity-linked notes. YYZ has now elected to convert part of their loans into common shares of Plyzer Spain representing 51 % of the company. As such, YYZ now controls the company and the ultimate direction of Plyzer Spain. As previously announced, YYZ has the right to finance up to US $2 M in senior equity-linked notes, that should the loans be converted, would end up in the ownership of 82 % of the equity of Plyzer Spain. Plyzer has not participated in the financing of the recent notes, as per the agreement between the parties, as the company does not currently have any excess capital on hand. Plyzer Spain is the operating company based in Barcelona, Spain that has developed and operates the ongoing business of Plyzer Intelligence, a SAS based data analytics platform. Although the company has paying customers and has cut costs where possible, the company is still operating at a deficit. It hopes to expand its offering into various verticals as well as expand globally (outside of Spain). With respect to the apps that had been developed for the purpose of price comparison, including the cannabis version, they are currently not being further developed nor likely to be continued. Plyzer Spain owns the rights to the apps and any intellectual property attached. 

With respect to the status of the outstanding convertible debt held by various funds in Plyzer, the face amount of approximately US $1.3 M has changed little since the last release. The company is in contact with the debt holders and hopes that at some time an organized plan to deal with the debt can be figured out. All of the funds are based in the United States. 

At this time, Plyzer has not engaged any firm for the purpose of public or investor relations. The Twitter feed that the company previously had is not active. Any published “newsletters’ that appear on various sites through the internet has not been organized or paid for by Plyzer in any way. At this time, Plyzer knows of no pending deals with any other companies for the purpose of financing or joint ventures other than the deal announced with YYZ. As the company does not have any available capital, there is no plan to execute any form of a stock buyback. YYZBCN Inc. is a Toronto, Ontario, Canada based private company. 

For More on PLYZ Subscribe Right Now!

PLYZ is gearing up and heating up in recent months skyrocketing out of the triple zeroes and emerging well into pennyland with recent highs of $0.006 per share.  The stock has been under heavy accumulation recently and volume has picked up substantially with PLYZ regularly trading several 100 million shares per day and topped $1.5 million in dollar volume on Friday alone. Microcapdaily first covered PLYZ on December 8 when the stock was triple zeroes; since than PLYZ has risen dramatically as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than PLYZ has. There is a lot to get excited about on PLYZ; PLYZ built Plyzer Intelligence; a tool built on artificial intelligence through internally developed algorithms, machine learning, geo-localization and product matching. It allows companies to apply business intelligence to their decisions through the simplification of big data. Brands and retailers can learn more about how their products, as well as their competitors’ products, are performing online. PLYZ was trading over $0.20 per share this time last year with no material changes to the Company. According to their filings the Company’s Spain subsidiary, Plyzer Spain s.l., now has 35 full time employees including 9 freelancers. Investors are anxiously awaiting PLYZ earnings announcement for the period ending March 30, 2020 set to be released on Tuesday, February 16. We will be updating on PLYZ on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with PLYZ.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in PLYZ either long or short and we have not been compensated for this article.

Continue Reading
2 Comments

2 Comments

  1. John N. Young

    February 25, 2021 at 1:42 pm

    Is there a possibility of Plyzer Technology executing a R/S?

    Thank you in anticipation

    John N. Young

  2. Len

    October 30, 2021 at 12:06 pm

    What is going on with this stock. Will it ever get back in compliance on the OTC Stock Market?

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions

Published

on

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development.

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development. The clinical-stage biopharmaceutical company has entered into a take-private transaction with MPM BioImpact, representing a significant milestone for Reunion Neuroscience. The transaction is valued at $13.1 million, a 43.1% premium to Reunion’s common shares’ 30-day volume-weighted average price.

Going private is a significant step for Reunion Neuroscience, as it means that a sizeable private-equity group or consortium of private-equity firms will purchase or acquire the stock of the publicly traded corporation.

To Discover the Inside Scoop on REUN, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Under the terms of the Arrangement Agreement, all holders of outstanding common shares of Reunion will be entitled to receive $1.12 in cash for each share held immediately before the effective time of the Arrangement. However, the agreement’s closing is subject to several conditions, which must be met before the transaction can be completed.

Hostile takeover?

While management and the board think it is a significant milestone achieved, others think differently – an investor rights law firm, Halper Sadeh LLC, is currently investigating it… The sale of Reunion Neuroscience to affiliates of MPM BioImpact for $1.12 per share in cash is currently being investigated by Halper Sadeh LLC.

The investigation concerns whether Reunion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Reunion shareholders; (2) determine whether MPM is underpaying for Reunion; and (3) disclose all material information necessary for Reunion shareholders to assess and value the merger consideration adequately. On behalf of Reunion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Reunion Neuroscience’s stock performance has been relatively volatile in recent years. The stock’s median target price, according to analysts’ forecasts, is $5.00, but there is a wide range of estimates, with a high of $20.00 and a low of $0.73. The current consensus among polled investment analysts is to buy $REUN stock. However, they’re a pre-revenue clinical-stage biopharmaceutical company, which means the last earnings reported a loss in the current quarter’s earnings per share – they’ve yet to generate any significant revenue. Until recently, shareholders experienced a significant decline in the stock’s value this year and were down ~54%  prior to the acquisition. There are ~9M shares in the float, with ~28% and ~13% held by insiders and institutional investors, respectively.

Overall, investors should carefully consider the potential risks and rewards associated with investing in Reunion Neuroscience, considering the wide range of price estimates and the company’s current financial performance. Thorough research and the advice of a financial professional are recommended before making any investment decisions.

We will update you on REUN when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Featured

Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells

Published

on

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601.

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601. They tested it on lymphoma cells in the lab, and the results showed that MT-601 can kill lymphoma cells resistant to another treatment called CD19 CAR T therapy, which is fascinating news considering many patients who receive CD19 CAR T therapy still experience a relapse within a year. 

“We have recently developed a long-term in vitro model to monitor the interaction of T cells with cancerous cells. Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited the growth of lymphoma cells as well as the growth of CD19 CAR-resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics. Marker has posted further details about this preclinical study on the Investor Relations section of its website.

Dr. Smith continued, “Specifically, we have developed an in vitro model which reproduces the CD19 antigen-negative tumor that causes relapse and observed the following:

To Discover the Inside Scoop on MRKR, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In this in vitro model, 98% of lymphoma cells were eliminated after a CD19-targeting CAR T cell product was administered.

While the CAR T cells significantly controlled lymphoma cell growth, we observed that three weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells resistant to CD19 CAR T cell administration started to grow.

These CD19 CAR-resistant lymphoma cells were tested for CD19 expression. They were shown to be negative for the CD19 surface antigen, which explained why they were no longer controlled with a second administration of anti-C19 CAR T cells, thus recapitulating the antigen-negative relapse observations in CAR relapsed/refractory lymphoma patients.

However, when MT-601, with its broad antigen recognition (Survivin, NY-ESO-1, WT-1, PRAME, MAGE-A4, SSX2), was added to this anti-CD19 CAR T cell resistant cell population, complete growth inhibition was observed.

These data highlight that MT-601 can potentially eliminate CD19 CAR T cell refractory tumors, indicating that MT-601 might offer a viable therapeutic option for lymphoma patients that have relapsed from previous CAR T cell interventions.”

MT-601 targets multiple substances on cancer cells and may provide longer-lasting results than CD19 CAR T therapy. Marker Therapeutics has started a clinical trial to test MT-601 on lymphoma patients who have relapsed after CD19 CAR T therapy or cannot receive it. The early lab results showed that MT-601 could inhibit the growth of lymphoma cells, including those resistant to CD19 CAR T therapy. The initial results have shown remarkable promise, and the team is thrilled to advance the testing of MT-601 in further clinical trials to evaluate its effectiveness and safety.

About Marker Therapeutics, Inc.

Marker Therapeutics is a company currently in the advanced stages of clinical research for developing innovative treatments in immuno-oncology. Their primary focus is on creating next-generation immunotherapies that utilize T cells, a type of immune cell, to target and fight against hematological malignancies (cancers of the blood, such as leukemia and lymphoma) and solid tumors (cancers that form in tissues or organs). These therapies aim to harness the immune system’s power to specifically recognize and eliminate cancer cells, offering potential new treatment options for patients with these types of cancers.

Capital structure

Marker Therapeutics has an outstanding total of 8.8M shares and presents a relatively small float of 6.64M shares available for public trading. Insiders hold approximately 12.82% of the shares, while institutional investors hold around 22.63%. Examining their trading history, the average volume typically hovers around 100,000 shares. In light of the positive news today, the trading activity trended much higher, with an impressive 27M shares traded at time of writing. This translates to a 270-fold increase compared to their average volume, also 4x their float.

It is essential to recognize the high volatility and rapid movements associated with Marker Therapeutics’ stock, primarily driven by the limited availability of shares. Such stocks tend to attract the interest of day and swing traders, given their propensity for swift gains or losses based on trading strategies. As evidence, a single positive news catalyst in the biotech sector can trigger a substantial surge in stock price and exponentially increase trading volume to unprecedented levels.

We will update you on MRKR when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PDPics from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.